促進蠕動 Symptomatic management of upper GI motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis; prevention of GI symptoms associated with use of dopamine-agonist anti-Parkinson agents.

Domperidone selectively blocks peripheral dopamine D2 receptors in the GI tract; it has antiemetic effects related to its action at the chemoreceptor trigger zone. Domperidone improves delayed gastric emptying and enhances antral and duodenal peristalsis but does not affect esophageal or colonic motility. Domperidone dose not cross the BBB and thus does not produce CNS and extrapyramidal effects.

Metabolism: Hepatic via CYP3A4, N-dealkylation and hydroxylation; Elimination Half-life: 7 hrs (increases to ~21 hrs in severe renal impairment)

Hypersensitivity to domperidone or any component of the formulation; patients with GI hemorrhage, mechanical obstruction, or perforation; concomitant use with ketoconazol.

Australian Drug Evaluation Committee's (ADEC) Category: B2

Enters breast milk/use caution

dry mouth (2%), Headache/migraine (1%), anxiety, and elevation in serum prolactin concentrations. Recent epidemiologic studies showing that the use of domperidone may be associated with serious ventricular arrhythmias and sudden cardiac death (cardiac arrest). The risk of cardiac adverse effects was highest in patients taking >30 mg of domperidone daily and in those patients over the age of 60 years.（UpToDate, March 2012 ）

Oral: Usual: 10 mg 3-4 times/day, 15-30 minutes before meals and at bedtime if needed.